60
Participants
Start Date
August 1, 2018
Primary Completion Date
August 1, 2020
Study Completion Date
August 1, 2021
anlotinib plus chemotherapy
Anlotinib (12mg QD PO d1-14, 21 days per cycle), Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
chemotherapy
Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang
Collaborators (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY
The First People's Hospital of Lianyungang
OTHER